Accessibility Menu
Carisma Therapeutics logo

Carisma Therapeutics(OTC) CARM

Current Price$0.01
Market Cap$188.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 Year-100%
1 Year-99%
1 Month-55%
Carisma Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-22
Carisma Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.05%USD 0.012026-07-15
1 month-55%USD 0.012026-06-22
3 month+1,025%USD 0.002026-04-23
Year to date-89.53%USD 0.042025-12-31
1 year-98.83%USD 0.392025-07-22
3 year-99.95%USD 8.402023-07-21
5 year-99.93%USD 6.812021-07-23
Since inception-99.89%USD 3.672023-03-08

Carisma Therapeutics Financials at a Glance

Market Cap

$188.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$52.63M

Net Income (TTM)

$8.04M

EPS (TTM)

$0.19

P/E Ratio

0.02

Dividend

$0.00

Beta (Volatility)

3.11 (High)

Price

$0.01

Volume

2,019

Open

$0.01

Previous Close

$0.00

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.56

Estimated Earnings Date

May 28, 2026

CARM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Carisma Therapeutics

Carisma develops cell therapies that aim to help the body fight cancer. Its main products use modified immune cells to target solid tumors. These therapies are designed for patients with difficult-to-treat cancers.

Lab Bench to Bedside: Carisma’s Main Offerings

  • Ex vivo cell therapy: Engineered immune cells (macrophages) designed to attack tumors; recent collaboration revenue was primarily from partnerships with Moderna.
  • CT-0508: Macrophage-based therapy for solid tumors; development stopped in 2024.
  • CT-0525: Personalized cell therapy targeting HER2 protein; development stopped in early 2025.
  • CT-1119: Therapy targeting mesothelin protein; paused due to lack of funding.
  • In vivo mRNA/LNP programs: Early-stage therapies using messenger RNA to direct immune cells; no commercial revenue yet.
  • Moderna collaboration: Joint research on new cancer and autoimmune therapies; all recent revenue from this partnership.

Plot Twists and Pivots: Growth & Expansion Moves

  • Signed exclusive license with the University of Pennsylvania for core technology in 2017.
  • Entered strategic collaboration with Moderna for cell therapy research (2022, expanded 2024).
  • Ceased all internal research and development in March 2025 to preserve cash.
  • Announced planned merger with OrthoCellix in June 2025; Carisma shareholders are expected to own approximately 10% of the new company, subject to certain assumptions including Carisma's net cash being approximately $0 and a $25 million concurrent investment.
  • All product development and expansion now paused pending merger outcome.

What Makes Carisma Stand Out (or Not)

Carisma’s main asset is its intellectual property in engineered immune cell therapies. Its partnership with Moderna gives it potential for future milestone payments. The company no longer develops products itself and relies on external partners for progress.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Operating expenses were $5.8M in Q2 2025, compared to $20.9M in Q2 2024.
  • Net loss was $9.8M in Q2 2025, compared to $11.2M in Q2 2024.
  • Cash and cash equivalents were $2.0M at June 30, 2025, compared to $17.9M at December 31, 2024.
  • All recent revenue came from the Moderna collaboration, not product sales.

Bottom Line

Carisma has shifted from developing therapies to seeking a merger for survival. Its future depends on external partnerships and the outcome of the OrthoCellix deal.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

46

CEO

Steven Kelly, MBA

Website

www.carismatx.com

Headquarters

Philadelphia, PA 19104, US

CARM Financials

Key Financial Metrics (TTM)

Gross Margin

99.27%

Operating Margin

58.60%

Net Income Margin

52.42%

Return on Equity

-92.22%

Return on Capital

N/A

Return on Assets

391.78%

Earnings Yield

50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$188.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.85M

Volume

2.02K

Avg. Volume

29.54K

Financials (TTM)

Gross Profit

$51.61M

Operating Income

$10.85M

EBITDA

$13.66M

Operating Cash Flow

-$22.42M

Capital Expenditure

$0.00

Free Cash Flow

-$22.42M

Cash & ST Invst.

$2.78M

Total Debt

$762.00K

Carisma Therapeutics Performance Analysis

Carisma Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 26,544,000N/A
20222022-12-31USD 9,834,000-63.0%
20232023-12-31USD 14,919,00051.7%
20242024-12-31USD 19,632,00031.6%
Carisma Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-317.9%
Q12025-03-312.1%
Q22025-06-30-100.0%
Q32025-09-30N/A
Carisma Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.04N/A
20222022-12-31USD -575.411563523.9%
20232023-12-31USD -2.59-99.5%
20242024-12-31USD -1.46-43.7%
Carisma Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-35.5%
Q12025-03-3147.6%
Q22025-06-30-4.5%
Q32025-09-30565.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$45.25M

+1236.8%

Gross Profit

$45.25M

+1236.8%

Gross Margin

100.00%

N/A

Market Cap

$188.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.09K

N/A

Employees

46

N/A

Net Income

$44.72M

+452.0%

EBITDA

$44.72M

+460.4%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$2.78M

-89.7%

Total Debt

$762.00K

-77.0%

Accounts Receivable

$1.64M

N/A

Inventory

$0.00

N/A

Long Term Debt

$609.00K

-28.9%

Short Term Debt

$153.00K

-93.8%

Return on Assets

3.92%

N/A

Return on Invested Capital

-111.25%

N/A

Free Cash Flow

$1.91M

+114.7%

Operating Cash Flow

$1.91M

+114.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ONCOOnconetix, Inc.
$0.86-2.32%
SPRCSciSparc Ltd.
$5.07+6.41%
ENVBEnveric Biosciences, Inc.
$1.33-0.75%
ASBPAspire Biopharma Holdings, Inc.
$7.45-3.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.62-0.21%
AALAmerican Airlines Group
$13.62-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.81-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.38+0.04%

Questions About CARM

What is the current price of Carisma Therapeutics?

Carisma Therapeutics is trading at $0.01 per share.

What is the 52-week range for Carisma Therapeutics?

Over the past 52 weeks, Carisma Therapeutics has traded between $0.00 and $0.56.

How much debt does Carisma Therapeutics have?

As of the most recent reporting period, Carisma Therapeutics reported total debt of $762.00K.

How much cash does Carisma Therapeutics have on hand?

Carisma Therapeutics reported $2.78M in cash and cash equivalents in its most recent financial results.

What is Carisma Therapeutics’s dividend yield?

Carisma Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services